Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease

The COVID-19 pandemic has caused a significant burden on public health worldwide. Currently, there are limited medications for the treatment of COVID-19 in patients with Parkinson's disorder (PD). Several antiviral drugs and other pharmacotherapies have shown promising results and are used by various delivery methods. Among the antiviral drugs, amantadine alone was reported to provide therapeutic benefit against COVID-19 in patients with PD. Here, we propose novel strategies for pulmonary drug delivery technology of antiviral drug, amantadine. As such pulmonary delivery of this drug or in combination with the additional antiviral drugs could be a more effective strategy for the treatment of COVID-19-related complications in patients with PD. Furthermore, the important benefits and limitations of this novel delivery technology will be discussed.

Automated summary

The COVID-19 pandemic has posed a significant burden on public health globally, and treatment options for COVID-19 in patients with Parkinson's disease are limited. Amantadine has shown therapeutic benefits against COVID-19 in PD patients. This article proposes novel strategies for pulmonary drug delivery technology of amantadine to potentially provide a more effective treatment for COVID-19-related complications in PD patients. The important benefits and limitations of this novel delivery technology are also discussed.